Table 2.
Clinical cases (n = 219) |
Controls (n = 67) |
||||
---|---|---|---|---|---|
Virus | Positive (%) | 95% CI | Positive (%) | 95% CI | p-value |
CanineCV | 71 (32.42) | 26.23–38.61% | 19 (28.35) | 17.56–39.14% | 0.530,988 |
CPV | 127a (57.99) | 51.46–64.52% | 1a (1.49) | 0–4.39% | <0.00001d |
2a | 57 (26.02) | 20.21–31.83% | 0 | – | – |
2b | 39 (17.80) | 12.74–22.86% | 0 | – | – |
2c | 28 (12.78) | 8.36–17.2% | 0 | – | – |
2b | 3 (1.36) | 0–2.89% | 1 (1.49) | 0–4.39% | – |
CCoV | 54 (24.65) | 19.97–29.33% | 1 (1.49) | 0–4.39% | 0.000026d |
CDV | 1c (0.45) | 0–1.33% | 1c (1.49) | 0–4.39% | 0.373,243 |
Samples containing a CPV vaccinal strain are included.
Vaccinal strain.
The detected CDV was a vaccinal strain.
Bold numbers indicate statistically significant p values (p < 0.05).